Company Overview and News

4
PRESS DIGEST - Canada - June 13

2018-06-13 reuters
June 13 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
CJREF SJR.B CJR.B SJR SJRWF SJR.PR.A SJR.A

4
Endless Content at Your Command: YouTube Now Streaming on Shaw BlueSky TV

2018-06-05 globenewswire
CALGARY, Alberta, June 05, 2018 (GLOBE NEWSWIRE) -- Shaw Communications Inc. today announced the integration of the YouTube and YouTube Kids apps into its intuitive BlueSky TV platform, marking the latest enhancement to the video experience. Users can now stream videos and keep up with livestreams from the comfort of their couches in a whole new way — revamping the TV and YouTube experience.
SJR.B SJR WIREX SJRWF SJR.PR.A SJR.A

4
Freedom Mobile and TransLink Partner to Provide Wireless Connectivity in SkyTrain Dunsmuir Tunnel

2018-05-23 globenewswire
Freedom Mobile customers can now talk, text and stream while riding the SkyTrain between Waterfront and Stadium-Chinatown stations
SJR.B SJR WIREX SJRWF SJR.PR.A SJR.A

4
Shaw Communications Completes Its First Successful 5G Technical Trials

2018-05-22 globenewswire
CALGARY, Alberta, May 22, 2018 (GLOBE NEWSWIRE) -- Shaw Communications Inc. (TSX:SJR.B) (TSX:SJR.PR.A) (TSX:SJR.PR.B) (NYSE:SJR) (TSX-V:SJR.A) today announced the successful completion of its first 5G technical trials in Calgary. Conducted in collaboration with Nokia, CableLabs and Rohde & Schwarz, Shaw’s trials leveraged 28GHz mmWave and 3.5GHz spectrum and demonstrated the significant and sustained speeds for the next generation of wireless technology.
SJR.B SJR WIREX SJRWF SJR.PR.A SJR.A

39
Why is Celanese (CE) Up 1.7% Since Last Earnings Report?

2018-05-16 zacks
It has been about a month since the last earnings report for Celanese Corporation (CE - Free Report) . Shares have added about 1.7% in that time frame.
HD SJR.B SJR SJRWF SJR.PR.A CE SJR.A APOG

90
Why is BofA (BAC) Up 4% Since Last Earnings Report?

2018-05-16 zacks
It has been about a month since the last earnings report for Bank of America Corporation (BAC - Free Report) . Shares have added about 4% in that time frame.
BAC BAC SJR.B SJR SJRWF SJR.PR.A SJR.A APOG

12
Shaw Communications (SJR) Down 2.3% Since Earnings Report: Can It Rebound?

2018-05-14 zacks
A month has gone by since the last earnings report for Shaw Communications Inc. (SJR - Free Report) . Shares have lost about 2.3% in that time frame.
CBSH SJR.B CBSHP SJR SJRWF SJR.PR.A ISRG CBCB SJR.A

23
Competition Bureau to 'shine a light' on internet industry with market study

2018-05-10 cbc.ca
The federal competition watchdog says he wants to "shine a light" on Canada's broadband internet providers with the public's comments on a market that is predominantly served by traditional phone and cable companies.
BCE RCIAF RCI SJR.B BCEXF SJR SJRWF SJR.PR.A TU SJR.A

4
New name could be in the works for Edmonton's Shaw Conference Centre

2018-05-01 cbc.ca
The Shaw Conference Centre, one of the most distinctive buildings in downtown Edmonton, could get a new name.
SJR.B SJR SJRWF SJR.PR.A SJR.A

4
Should You Buy Cogeco Communications And Its Growing Dividend?

2018-04-27 seekingalpha
Cogeco Communications is the fourth-largest cable company in Canada and owns quality cable assets in the United States.
SJR.B SJR SJRWF CGEAF SJR.PR.A SJR.A

84
2 High-Yield Blue Chips Worth Buying Today But One Is Far More Likely To Beat The Market

2018-04-26 seekingalpha
Telecom has had a rough year, largely thanks to concerns over cord cutting, a price war in wireless, and rising interest rates.
RCI SJR.B SJR SJRWF SJR.A BCE CHTR RCIAF FTRPR SJR.PR.A MOBAF TU FTR

4
Is Shaw Communications A Good Long-Term Investment Choice?

2018-04-23 seekingalpha
Shaw Communications is a leading cable operator in Western Canada and currently, the fourth largest wireless communication service provider in the country.
SJR.B SJR SJRWF SJR.PR.A QBCRF SJR.A

71
Top Stock Reports for UnitedHealth, Netflix & Caterpillar

2018-04-18 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), Netflix (NFLX) and Caterpillar (CAT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
GD SJR.B CAT DGX INFY SJR NFLX SJRWF THS SJR.A INFY SJR.PR.A UNH LAD

14
Second Cup Coffee Chain Looks To Add Marijuana

2018-04-18 seekingalpha
Second Cup $3.61 (Toronto symbol SCU, (OTC:SCUPF); Shares outstanding: 17.04 million; Market cap: $61.52 million; www.secondcup.com) is a Canada-based specialty coffee retailer with 286 cafes of which 12 are company-operated and the remaining are operated by franchisees.
TWMJF SJR.B NACNF WEED SJR CAO SJRWF ADWPF SJR.PR.A SCU SCUPF SJR.A

55
Rogers Communications (RCI) Q1 Earnings: What's in Store?

2018-04-17 zacks
Rogers Communications Inc. (RCI - Free Report) is set to release first-quarter 2018 results on Apr 19. The company beat the Zacks Consensus Estimate in the trailing four quarters, with an average positive surprise of 4.97%. In fourth-quarter 2017, earnings of 69 cents per share outpaced the Zacks Consensus Estimate by a penny. Although revenues of $2.86 billion lagged the consensus mark, the figure increased 3% year over year driven by solid result from the Wireless segment.
RCI SJR.B APO.PRB APO.PRA WDC MS.PRE SJR MS.PRF SJRWF MS.PRG MS.PRA APO PAYC SJR.A BCE RCIAF MS.PRI MS.PRK SJR.PR.A MS

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...